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Background: Apremilast, a specific inhibitor of phosphodiesterase 4, modulates pro-inflammatory and anti-
inflammatory cytokine production.
Objectives: Apremilast’s effect on patient-reported outcomes (PROs) in patients with moderate to severe psoriasis
was evaluated in a phase IIb randomized, controlled trial (NCT00773734).
Methods: In this 16-week, placebo-controlled study, 352 patients with moderate to severe plaque psoriasis received
placebo or apremilast (10, 20, or 30 mg BID). PROs included Dermatology Life Quality Index (DLQI), pruritus visual
analog scale (VAS), and Short-Form Health Survey (SF-36) to assess health-related quality of life (HRQOL). Changes
from baseline and patients reporting improvements ≥minimum clinically important differences (MCID) were
analyzed. Correlations between changes across various PRO instruments were explored.
Results: Baseline DLQI (>10 points) and SF-36 MCS and domain scores indicated impairments in HRQOL. At 16 weeks,
greater improvements from baseline in DLQI scores were reported with apremilast 20 (−5.9) and 30 mg BID (−4.4)
compared with placebo (1.9; P≤0.005 for both), and a greater proportion of patients reported improvements ≥MCID
(20 mg BID, 49.4%, 30 mg BID, 44.3%) versus placebo (25.0%; P<0.04). Greater improvements from baseline in pruritus
VAS scores were reported with apremilast 20 (−35.5%) and 30 mg BID (−43.7%) versus placebo (−6.1%; P≤0.005).
Significant and clinically meaningful improvements in SF-36 mental component summary scores (P≤0.008) and Bodily
Pain, Mental Health, and Role-Emotional domains were reported with all apremilast doses (P<0.05), and Social
Functioning with 20 and 30 mg BID (P<0.05) and Physical Functioning with 20 mg BID (P<0.03). Correlations between
SF-36 scores and DLQI were moderate (r>0.30 and ≤0.60) and low between SF-36 and pruritus VAS (r≤0.30), indicating
they measure different aspects of the disease.
Conclusions: Apremilast treatment resulted in improved HRQOL, including DLQI and pruritus VAS over 16 weeks of
treatment, in patients with moderate to severe psoriasis.
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Psoriasis is a chronic inflammatory disease that affects
approximately 1% to 3% of the worldwide population
[1,2]. Individuals with psoriasis report impaired health-
related quality of life (HRQOL), ranging from physical
discomfort and limitations in activities of daily living to
psychosocial problems and emotional distress [3-7]. Fur-
thermore, the severity of psoriasis symptoms, and prur-
itus in particular, has been linked to the degree of
HRQOL impairment [3,4].
Many therapies for psoriasis treatment improve
HRQOL [8-10]. Despite this, each therapy’s benefit can
be compromised by poor tolerability, adverse events, and
route of administration (particularly injection/infusion re-
actions) [11,12]. These limitations underscore the persist-
ent unmet need for additional treatment options for
psoriasis [13]. As new therapies become available for man-
aging psoriasis, it is important to evaluate their impact on
patient-reported HRQOL.
Research over the past decade in inflammatory dis-
eases such as psoriasis has focused upon modulation of
cyclic adenosine monophosphate (cAMP), a naturally
occurring intracellular secondary messenger that main-
tains immune homeostasis by modulating production of
pro-inflammatory and anti-inflammatory cytokines
[14,15]. Phosphodiesterase 4 (PDE4) is a cAMP-specific
PDE and the dominant PDE in inflammatory cells. PDE4
inhibition elevates intracellular cAMP, which in turn
down-regulates the inflammatory response [16-19].
Apremilast (CC-10004; Celgene Corporation, Summit, NJ,
USA) is a small molecule that specifically inhibits PDE4,
thereby elevating intracellular cAMP levels. Elevated
intracellular cAMP reduces pro-inflammatory mediators,
such as tumor necrosis factor-α, interleukin-23, and inter-
feron-γ, and increases production of anti-inflammatory
mediators, such as interleukin-10 [18]. Clinical studies
have demonstrated the efficacy and tolerability of
apremilast in moderate to severe psoriasis and psoriatic
arthritis (PsA) [20-22].
In this phase IIb, multicenter, randomized, controlled
trial (RCT), orally administered apremilast (10 mg BID,
20 mg BID, or 30 mg BID) resulted in dose-dependent
efficacy for the treatment of moderate to severe plaque
psoriasis [20]. A significantly greater proportion of pa-
tients receiving apremilast 20 mg (28.7%) and 30 mg
BID (40.9%) achieved ≥75% mean reductions from base-
line in Psoriasis Area and Severity Index (PASI-75)
scores compared with placebo (P<0.001) after 16 weeks
of treatment [20]. Reductions in baseline PASI scores
were evident by week 2, with a separation across doses
observed by weeks 2 to 4; improvements were
maintained over 24 weeks' treatment. Significant im-
provements in pruritus visual analog scale (VAS), static
Physician’s Global Assessment, and body surface area(BSA) scores were also reported. It is hypothesized that
clinical improvements would be accompanied by improve-
ments in patient-assessed HRQOL. This report summa-
rizes the impact of apremilast on patient-reported
outcomes (PROs) over the initial 16-week placebo-
controlled treatment phase of this trial.Materials and methods
Study design
This phase IIb RCT was conducted at 35 sites in the
United States and Canada between September 2008 and
November 2009. Methods, including enrollment, study
design, and procedures, have been previously published
[20]. Briefly, men and women ≥18 years of age with
stable, chronic, moderate to severe plaque psoriasis
(PASI ≥12 and BSA ≥10% for ≥6 months) who were can-
didates for phototherapy or systemic therapy were en-
rolled and randomized 1:1:1:1 to receive apremilast 10,
20, or 30 mg BID or placebo for 16 weeks. At week 16,
placebo patients were re-randomized 1:1 to apremilast
20 or 30 mg BID until week 24 in blinded fashion; all
other patients continued their assigned dose of
apremilast. Throughout the trial, concomitant photo-
therapy and use of systemic and biologic agents were
prohibited. Use of topical agents was also prohibited,
with the exception of Eucerin® cream for body lesions;
low-potency corticosteroids for facial, axillary, and groin
psoriasis lesions; and coal tar shampoo or salicylic acid
preparations for scalp lesions. All patients provided writ-
ten informed consent before study-related procedures
were done, and the protocol and consent were approved
by institutional review boards or ethics committees at all
investigational sites.PRO assessments
Changes from baseline to week 16 and improvements ≥
minimum clinically important differences (MCID) were
determined for PROs, including the Dermatology Life
Quality Index (DLQI), pruritus VAS scores, and Short-
Form Health Survey version 2 (SF-36) (Table 1). The
DLQI is a 10-item questionnaire that assesses the impact
of skin disease on HRQOL over the previous week.
Scores for each item range from 0 (not at all affected) to
3 (very much affected); total scores range from 0 to 30
and those >10 represent a very large impact on HRQOL
[28]. The pruritus VAS assesses severity of psoriasis-
related pruritus over the past 24 hours, on a 0- to 100-
mm scale (0=no itch, 100=worst itch imaginable). SF-36 is
a generic HRQOL questionnaire with 36 questions com-
bined into 8 domains, scored from 0 (worst) to 100 (best).
Domain scores are combined into physical (PCS) and
mental component summary (MCS) scores with norma-
tive scores of 50 and standard deviations (SDs) of 10.
Table 1 Overview of HRQOL assessment instruments and MCID [23-27]
Instrument Description Scale MCID
Pruritus VAS ● Pruritus visual analog scale 0–100 mm, including “anchors” 10.0 points
(best to worst)
DLQI ● Dermatology Life Quality Index 0–30 points 5.0 points







SF-36 domains* ● Patient report, 36 items 0–100 mm 5.0 points








SF-36 PCS and MCS scores ● Calculated based upon domain scores Normative value: mean=50, SD=10 2.5 points
*Based on transformed scale scores.
HRQOL, health-related quality of life; MCID, minimum clinically important differences; MCS, mental component summary; PCS, physical component summary;
SF-36, 36-Item Short-Form Health Survey version 2.
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PROs were evaluated based on the intent-to-treat popu-
lation using last-observation-carried-forward (LOCF) to
account for missing values. Week 16 changes from base-
line in DLQI and SF-36 scores were examined using
ANCOVA, with treatment as a factor and baseline as a
covariate. Week 16 percent change from baseline in
mean pruritus VAS scores was compared using the
Wilcoxon test for each apremilast group versus placebo.
If either PCS and/or MCS scores of SF-36 were statisti-
cally significant, significance was tested for the individual
domain scores, without P value corrections for multipli-
city. Mean changes from baseline in domain scores are
displayed using spydergrams [29], with quantification of
improvements using the health utility SF-6D measure,
after the method of Ara and Brazier [30,31]. As a bench-
mark comparison, US normative data were calculated
based on age and gender distribution of the protocol
population [32]. Pearson correlations (r) were deter-
mined for mean changes from baseline between the gen-
eric SF-36 Bodily Pain (BP) and Vitality (VT) domains
and MCS scores at week 16 with disease-specific DLQI
and pruritus VAS scores. Correlations >0.30 to ≤0.60
were considered moderate and >0.60 high [33]. These




The majority of patients (N=352) were men (62.8%),
white (92.9%), and obese (mean ± SD body mass index,
31.2 ± 7.1 kg/m2). Patients had plaque psoriasis for a
mean of 19 years and 21% had PsA (Table 2).
PRO assessments
DLQI
Mean DLQI scores were similar and >10 across all treat-
ment groups at baseline (Table 3). At week 16, mean
DLQI scores were significantly lower (vs. placebo) with
apremilast 20 mg BID (P<0.001) and 30 mg BID
(P=0.005), but not with 10 mg BID (P=0.132). Twenty-
two (25.0%) placebo, 30 (33.7%) apremilast 10 mg BID
(P=0.249), 43 (49.4%) 20 mg BID (P=0.001 vs. placebo),
and 39 (44.3%) 30 mg BID (P=0.011 vs. placebo) patients
reported improvements ≥MCID.
Pruritus VAS
Baseline pruritus VAS scores were well matched across
treatment groups (Table 3). Significantly greater reductions
Table 2 Baseline demographic and clinical characteristics of the enrolled population
Characteristic Placebo (n=88) Apremilast BID Total (N=352)
10 mg (n=89) 20 mg (n=87) 30 mg (n=88)
Age (years) 44.1 ± 13.7 44.4 ± 14.0 44.6 ± 12.6 44.1 ± 14.7 44.3 ± 13.7
Male 53 (60.2) 63 (70.8) 55 (63.2) 50 (56.8) 221 (62.8)
Race
White 83 (94.3) 82 (92.1) 82 (94.3) 80 (90.9) 327 (92.9)
Black 1 (1.1) 2 (2.2) 1 (1.1) 2 (2.3) 6 (1.7)
Asian 4 (4.5) 3 (3.4) 2 (2.3) 4 (4.5) 13 (3.7)
Other 0 (0.0) 2 (2.2) 2 (2.3) 2 (2.3) 6 (1.7)
Height (cm) 171.2 ± 8.6 171.5 ± 10.2 171.7 ± 9.6 171.2 ± 10.7 171.5 ± 9.6
Weight (kg) 90.3 ± 21.4 95.7 ± 23.2 89.9 ± 20.2 91.2 ± 23.1 91.8 ± 22.0
BMI (kg/m2) 30.8 ± 6.7 32.5 ± 7.4 30.4 ± 6.2 31.1 ± 7.8 31.2 ± 7.1
Total PASI score 18.1 ± 5.7 18.1 ± 6.3 18.5 ± 7.3 19.1 ± 7.1 18.5 ± 6.6
BSA 21.0 ± 11.2 21.3 ± 11.4 20.7 ± 12.4 25.0 ± 15.4 22.0 ± 12.8
+ History PsA 17 (19.3) 20 (22.5) 16 (18.4) 21 (23.9) 74 (21.0)
Plaque psoriasis history (years) 19.6 ± 11.6 18.0 ± 12.4 19.2 ± 12.2 19.2 ± 12.0 19.0 ± 12.0
Previous systemic therapy for psoriasis 39 (44.3) 47 (52.8) 43 (49.4) 47 (53.4) 176 (50.0)
Values are mean ± SD or n (%). BMI, body mass index; BSA, body surface area; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.
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reported with apremilast 20 mg BID (P=0.005) and 30 mg
BID (P<0.001), but not with 10 mg BID (P=0.366) versus
placebo. Thirty-nine (44.3%) placebo, 47 (52.8%) apremilast
10 mg BID (P=0.294), 53 (60.9%) 20 mg BID (P=0.034 vs.
placebo), and 56 (63.6%) 30 mg BID patients (P=0.015)
reported improvements ≥MCID.
SF-36 MCS and PCS scores
At baseline, mean SF-36 MCS scores across treatment
groups were 0.5 SDs lower than US normative scores of
50 (range: 45.7–47.0), whereas SF-36 PCS scores approx-
imated 50 (range 48.6–49.3). After 16 weeks of treat-
ment, mean changes from baseline in MCS scores were
significantly greater with apremilast 10, 20, or 30 mg
BID than placebo (Figure 1), exceeding MCID, andTable 3 Summary DLQI and pruritus VAS scores at week 16
Patient-reported outcome Placebo (n=88)
DLQI
Baseline 10.7 ± 6.7
Week 16 8.6 ± 7.6
Change from baseline −1.9 ± 5.2
Pruritus VAS
Baseline 55.5 ± 25.5
Week 16 45.6 ± 30.2
Percent change from baseline −6.1 ± 76.4
*P≤0.005 vs placebo.
Values are mean ± SD. DLQI, Dermatology Life Quality Index; VAS, visual analog scaapproaching US normative values (range: 49.0–49.9).
Week 16 mean changes from baseline in PCS scores
were numerically greater with apremilast 10, 20, and 30
mg BID than placebo but were neither statistically sig-
nificantly nor clinically meaningful.
SF-36 domain scores
At baseline, SF-36 domain scores were generally well
matched between study groups and equaled or were
within 10 points of age- and gender-matched normative
scores. At week 16, no significant changes from baseline
in any domain were evident in the placebo group.
In patients receiving apremilast 10 mg BID, mean
changes from baseline were statistically significant and ≥
MCID in three of eight domains: BP, Mental Health
(MH), and Role-Emotional (RE; P=0.007 for all; Figure 2).Apremilast BID
10 mg (n=89) 20 mg (n=86) 30 mg (n=88)
10.8 ± 6.3 11.6 ± 7.0 10.6 ± 6.2
7.6 ± 6.3 5.8 ± 6.0 6.0 ± 6.2
−3.2 ± 6.0 −5.9 ± 6.7* −4.4 ± 5.1*
54.1 ± 23.5 58.3 ± 26.7 55.3 ± 25.5
39.0 ± 27.8 35.2 ± 29.2 31.6 ± 30.0
−10.2 ± 100.8 −35.5 ± 66.0* −43.7 ± 46.8*
le.
Figure 1 Mean change from baseline in SF-36 physical and mental component summary scores at week 16. P values (vs. placebo), based
on ANCOVA, with treatment as the factor, and baseline value as the covariate. An increase in score indicates improvement. MCID, minimal
clinically important difference; SF-36, 36-item Short-Form Health Survey.
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baseline were statistically significant in five domains
(Physical Functioning [PF; P=0.028], BP [P=0.025], Social
Functioning [SF; P=0.046], RE [P=0.004], and MH
[P=0.012]), and ≥MCID in six domains (PF, BP, SF, RE,
MH, and RP) (Figure 3). Improvements reported in the
apremilast 30 mg BID group were statistically significant
in four domains: BP (P=0.023), SF (P=0.028), RE
(P=0.006), and MH (P=0.013) and ≥MCID in three (BP,
SF, and RE) (Figure 4). Across all three active doses, sta-
tistically significant improvements were reported in BP,
MH, and RE, and in SF for apremilast 20 and 30 mg
BID, contributing to statistically significant changes in
MCS scores. Mean changes from baseline in SF-6D
scores were 0.042 and 0.052, respectively, in theFigure 2 SF-36 domain scores at baseline and week 16 with apremila
apremilast 10 mg BID versus US age-/gender-matched norms (lavender) and
points = 2× MCID). An increase in score indicates improvement. Treatment-as
in three of eight domains. MCID, minimal clinically important difference; SF-36apremilast 10 and 20 mg BID dose groups, exceeding
minimum important differences (MID), and 0.036, ap-
proaching MID, with 30 mg BID.
Correlations among DLQI, pruritus VAS, and SF-36 scores
Correlations observed between generic SF-36 MCS, BP,
and VT domain scores and disease-specific DLQI and
pruritus VAS scores were analyzed (Table 4). With all
doses of apremilast, statistically significant moderate
correlations were observed between SF-36 BP domain
and DLQI (P<0.001) and MCS scores and DLQI
(P<0.001). Correlations between SF-36 VT domain and
DLQI were overall low, but statistically significant with
apremilast 20 mg (P=0.003) and 30 mg BID (P=0.040).
Correlations between BP domain and pruritus VAS werest 10 mg BID. Spydergram of SF-36 domain scores in patients receiving
baseline (dark blue). Gridlines represent changes of 10 points each (10
sociated improvements (light blue) are statistically significant and ≥MCID
, 36-item Short-Form Health Survey. *≥MCID.
Figure 3 SF-36 domain scores at baseline and week 16 with apremilast 20 mg BID. Spydergram of SF-36 domain scores in patients
receiving apremilast 20 mg BID versus US age-/gender-matched norms (lavender) and baseline (dark blue). Gridlines represent changes of 10
points each (10 points = 2× MCID). An increase in score indicates improvement. Treatment-associated improvements (light blue) are statistically
significant in five and≥MCID in six of eight domains. MCID, minimal clinically important difference; SF-36, 36-item Short-Form Health Survey. *≥MCID.
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correlations between VT domain and MCS scores and
pruritus VAS were low, and statistically significant with
apremilast 30 mg BID only.
Discussion
In this RCT, patients with moderate to severe plaque
psoriasis reported impairments in disease-specific and
generic measures of HRQOL at baseline, evidenced by
mean DLQI scores >10 and SF-36 MCS scores 0.5 SDs
below US age-/gender-matched norms. StatisticallyFigure 4 SF-36 domain scores at baseline and week 16 with apremila
receiving apremilast 30 mg BID versus US age-/gender-matched norms (lav
points each (10 = 2× MCID of 5 points). An increase in score indicates imp
statistically significant in four of eight domains and ≥MCID in three of eigh
item Short-Form Health Survey.*≥MCID.significant and clinically meaningful improvements in
SF-36 MCS and domain scores were reported by pa-
tients treated with apremilast, most evident in the 20-
and 30-mg BID dose groups, mirrored by decreases in
disease-specific DLQI and pruritus VAS scores. In con-
trast, patients receiving placebo reported little change or
deterioration from baseline in HRQOL. Correlations be-
tween SF-36 MCS, BP, and VT scores and DLQI were
moderate and, in general, statistically significant. Corre-
lations between SF-36 scores and pruritus VAS were
moderate to low, indicating that they measure differentst 30 mg BID. Spydergram of SF-36 domain scores in patients
ender) and baseline (dark blue). Gridlines represent changes of 10
rovement. Treatment associated improvements (light blue) are
t domains. MCID, minimal clinically important difference; SF-36, 36-
Table 4 Correlations of changes in SF-36 BP, VT, and MCS
scores with changes in DLQI and pruritus VAS scores at
week 16
Placebo Apremilast BID
10 mg 20 mg 30 mg
SF-36 BP with DLQI −0.45* −0.32* −0.52* −0.35*
P<0.001 P=0.002 P<0.001 P=0.001
SF-36 VT with DLQI 0.38* −0.18 −0.33* −0.23
P<0.001 P=NS P=0.003 P=0.040
SF-36 MCS with DLQI −0.57* −0.41* −0.42* −0.31*
P<0.001 P<0.001 P<0.001 P=0.004
SF-36 BP with pruritus VAS −0.39* −0.27 −0.43* −0.30
P<0.001 P=0.013 P<0.001 P=0.005
SF-36 VT with pruritus VAS −0.36* 0.01 −0.11 −0.23
P=0.001 P=NS P=NS P=0.034
SF-36 MCS with pruritus VAS −0.35* −0.21 −0.12 −0.35*
P=0.001 P=NS P=NS P=0.001
*Moderate correlations (r>0.30 and ≤0.60).
BP, Bodily Pain; DLQI, Dermatology Life Quality Index; MCS, mental component
summary; SF-36, Short-Form 36 Health Survey; VAS, visual analog scale;
VT, Vitality.
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assessing efficacy using multiple instruments.
Interpretation and implications
Growing evidence clearly shows that impairments in
HRQOL are a large component of the disease burden
imposed by psoriasis. These results are in line with
national survey findings that show the majority of indi-
viduals with psoriasis experience emotional as well as
physical disease-related problems [34]. In that survey,
63% of respondents reported that psoriasis impacts their
emotional well-being, marked by feelings of helplessness,
anger, embarrassment, and frustration. Given the gener-
ally high level of emotional distress patients report re-
garding psoriasis symptoms, it is important to describe
the potential impact of treatment on emotional func-
tioning. Emotional distress has been linked to onset of
psoriasis flares, more severe symptoms, and presence of
lesions in visible locations [3,35] and may contribute to
heightened risk of major depressive disorder, often seen
in this patient population [5,6,36]. This trial contributes
to other RCT data demonstrating that efficacious treat-
ment of moderate to severe psoriasis results in improve-
ments in HRQOL [7-9,37,38]. Consistent with findings
from other studies [7], psoriasis appears to have rela-
tively greater impact on mental health rather than phys-
ical domains, as patients report larger decrements in RE
and SF and to a lesser degree BP domains. This suggests
that the impact of physical well-being on mental health
might well depend on the nature of the physical impair-
ment, as skin disease may have a disproportionatelylarge effect on mental functioning and ensuing HRQOL
whereas joint disease in PsA has more impact on PF, BP,
and VT domains. These data demonstrate moderate cor-
relations between improvements in disease-specific func-
tioning, based on DLQI, and broader improvements in
SF-36 MCS scores and BP, SF, and RE domains. This
likely reflects improvements in painful psoriatic plaques
and/or joint pain associated with comorbid PsA, al-
though only a minority of patients reported the presence
of arthritis. The ability to measure treatment efficacy
based on broader generic instruments has implications
when considering comparisons with normative popula-
tions as well as across disease states. Disease-associated
decrements in HRQOL reported by patients with psoria-
sis indicate that a multipronged approach could enhance
assessment of treatment effectiveness. This approach
should encompass clinical signs and symptoms, as well
as patient-reported HRQOL, using both disease-specific
and generic instruments.
Apremilast clinical data
As described in a separate report [20], the primary re-
sults of this study demonstrate the efficacy and tolerabil-
ity of apremilast 20 and 30 mg BID over 24 weeks in
patients with moderate to severe plaque psoriasis, in-
cluding significant improvements in PASI, pruritus,
static Physician’s Global Assessment, and BSA scores.
The most frequently reported adverse events were head-
ache, nausea, vomiting, nasopharyngitis, and upper re-
spiratory tract infection. The majority of adverse events
(>96%) were mild or moderate in severity, and rates of
discontinuations due to adverse events were generally
low (≈10%). Gastrointestinal events were generally tran-
sient. Importantly, no opportunistic infections were
reported, and no serious infections were considered re-
lated to apremilast [20].
The tolerability findings are important in their rela-
tionship to the improved HRQOL seen in this study.
While improvement in the severity of disease can be
expected in most cases to improve HRQOL, there are
some instances in which tolerability and safety issues
may abrogate this benefit. The results of the current
analysis indicate that this was not the case with
apremilast. While the most commonly reported adverse
events were related to gastrointestinal complaints and
headache, this did not appear to outweigh the benefit of
therapy, and resulted in an overall improvement in
HRQOL.
On the basis of phase II findings, further examination
of the efficacy and safety of apremilast for the treatment
of psoriasis is underway in phase III studies. The ES-
TEEM (Efficacy and Safety Trial Evaluating the Effects
of apreMilast in psoriasis) clinical trial program includes
two 52-week RCTs, each with a 16-week placebo-
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responders, and long-term, open-label extension to as-
sess the efficacy, tolerability, and effects of apremilast on
HRQOL in patients with moderate to severe plaque
psoriasis. Recently, topline results from the ESTEEM 1
trial were presented [39]. At week 16, a significantly
greater proportion of patients receiving apremilast 30
mg BID achieved PASI-75 (33.1%) and PASI-50 (58.7%)
compared with placebo (5.3% and 17.0%; P<0.0001 for
both). Apremilast was also associated with significant
improvements in static Physician’s Global Assessment,
pruritus VAS, and DLQI as well as difficult-to-treat
nail and scalp psoriasis. Apremilast was well-tolerated
and no new safety or laboratory signals were detected.
Additional results are anticipated. In addition, apremilast
is currently being investigated in phase III clinical trials
for the treatment of PsA and ankylosing spondylitis.
Limitations
The study enrolled patients with moderate to severe
plaque psoriasis and results may not be applicable to pa-
tients with other forms of psoriasis. This report is based
on PROs after 16 weeks of treatment, although a separ-
ate publication indicates that improvements with active
therapy are generally maintained over 24 weeks of treat-
ment [20]. Ongoing phase III studies are expected to
yield valuable information.
Conclusions
Moderate to severe plaque psoriasis is associated with a
negative impact on HRQOL, including pain and social
and emotional functioning. Assessment of clinical signs
and symptoms, as well as PROs, is useful in determining
the impact of psoriasis and the clinical efficacy of treat-
ment. In this study, apremilast 20 mg and 30 mg BID
consistently resulted in statistically significant and clinic-
ally meaningful improvements in disease-specific and
generic measures of HRQOL in patients with long-
standing, moderate to severe plaque psoriasis. Findings
indicate that the benefit:risk profile of apremilast results
in a net improvement in HRQOL for the patient.
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